INTEGRATE: An integrated treatment to decrease psychological distress and substance use in young people seeking help for emerging mental illness.

Funding

Charities/Societies/Foundations,Gandel Philanthropy

Scientific enquiries

Dr Gillinder Bedi

Brief Summary

The aim of the study is to test whether a new integrated psychological treatment (INTEGRATE) improves mental health difficulties and decreases the risk of problematic substance use in young people, compared with usual treatment. Young people between the ages of 12 and 25 (inclusive) will be randomised to receive either i) the INTEGRATE therapy, or ii) treatment as usual (TAU), for 16 weeks in a double-blind, randomised controlled trial (RCT), with followup to 12 months. The primary hypothesis is .... The aim of the study is to test whether a new integrated psychological treatment (INTEGRATE) improves mental health difficulties and decreases the risk of problematic substance use in young people, compared with usual treatment. Young people between the ages of 12 and 25 (inclusive) will be randomised to receive either i) the INTEGRATE therapy, or ii) treatment as usual (TAU), for 16 weeks in a double-blind, randomised controlled trial (RCT), with followup to 12 months. The primary hypothesis is that young people who are randomised to receive the INTEGRATE intervention will decrease their alcohol and other drug use compared to participants in the TAU group.
Read more

Key Inclusion Criteria

Aged 12-25 years inclusive; Seeking treatment at headspace for mental ill-health; At screening, either: Self-reported use during the past month of greater than or equal to 4x use of cannabis or alcohol, greater than or equal to 1x use of another illicit drug (e.g. methamphetamine, ecstasy, cocaine etc.), assessed using the Timeline Follow-back (TLFB; participants using alcohol only will be required to have consumed in excess of Australian National Guidelines for Alcohol Consumption of >4 standar .... Aged 12-25 years inclusive; Seeking treatment at headspace for mental ill-health; At screening, either: Self-reported use during the past month of greater than or equal to 4x use of cannabis or alcohol, greater than or equal to 1x use of another illicit drug (e.g. methamphetamine, ecstasy, cocaine etc.), assessed using the Timeline Follow-back (TLFB; participants using alcohol only will be required to have consumed in excess of Australian National Guidelines for Alcohol Consumption of >4 standard drinks on greater than or equal to 1 occasion in the past month); OR Self-reported, clinically-relevant binge alcohol use (i.e. at least 4 standard drinks on at least one occasion) in the past 3 months, which resulted in clear potential for harm or high-risk behaviour (i.e. blackouts, hospital attendance, driving while intoxicated); Treatment with either a stable dose of an antidepressant or no antidepressant greater than or equal to 2 weeks at screening; Sufficient English fluency to complete treatment and participate in the study; Ability to provide written informed consent – where the participant is under 18 years of age, a parent or guardian will also be required to provide written informed consent or the young person will consent as a mature minor.
Read more

Key Exclusion Criteria

Lifetime DSM-V diagnosis of a psychotic or bipolar disorder (assessed using structured clinical interview; SCID-5) OR current DSM-V diagnosis of either post-traumatic stress disorder, obsessive compulsive disorder, or an eating disorder for which the young person is seeking treatment; Currently in AOD specific treatment, or open to referral to AOD treatment at headspace; Current treatment with antipsychotic medication or mood stabiliser Acute suicidality at screening, determined by clinical risk .... Lifetime DSM-V diagnosis of a psychotic or bipolar disorder (assessed using structured clinical interview; SCID-5) OR current DSM-V diagnosis of either post-traumatic stress disorder, obsessive compulsive disorder, or an eating disorder for which the young person is seeking treatment; Currently in AOD specific treatment, or open to referral to AOD treatment at headspace; Current treatment with antipsychotic medication or mood stabiliser Acute suicidality at screening, determined by clinical risk assessment; Participation in another trial, which is likely to affect data for this study, determined by the Investigator; Intellectual disability, as indicated by estimated or documented IQ of 70 or less.
Read more